Fig. 7: Variations in clonal composition in BM MNCs during HMA treatment.
From: Clinical response to azacitidine in MDS is associated with distinct DNA methylation changes in HSPCs
a Variant allele shifts in each patient over (left) injection phase, and (right) oral phase. Each column shows an individual patient with heatmap representation of VAF for each variant allele at start and end of the treatment phase (or, where relevant, during the oral phase, at progression). Bar plots show total number of variant alleles detected at each time point and are coloured by clinical response across the relevant treatment phase. b Clonal shifts in representative patients. Upper panels: Nightingale plots show VAF for each variant at diagnosis (C1), following 6 treatment cycles (C7) and following 12 treatment cycles/at progression (C12). Lower panels: Methylation level relative to C1D1 in PB across the entire course of treatment. c Correlation between global changes in methylation and shifts in variant allele burden for the four most frequently mutated genes in this cohort. Plots show composite data; each data point indicates a change in VAF across either injection or oral treatment phase and the average global methylation relative to C1D1 over the same treatment phase. r = two-sided spearman correlation coefficient.
